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Abstract
Simultaneous or sequential haemorrhage and thrombosis in the presence of a prolonged activated partial
thromboplastin time (aPTT) is a rare occurrence: we describe the case a 37 year old lady who developed post-
delivery deep vein thrombosis treated with low molecular heparin and warfarin followed a week later by extensive
bruising over legs and forearms, a significant drop in haemoglobin and a very prolonged aPTT. Further tests
revealed an acquired factor VIII inhibitor at 35 Bethesda Units. We discuss the clinical and laboratory implications
and provide a literature review of simultaneous thrombophilia and haemophilia in the presence of a prolonged
aPTT.
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Background
The differential diagnosis of a prolonged aPTT (acti-
vated partial thromboplastin time) is manifold and
necessitates an algorithm to indicate factor deficiencies
or the presence of inhibitors that could be lupus like,
heparin like or specific to a clotting factor [1]. A quick
and correct laboratory diagnosis is of the utmost impor-
tance in the emergency setting when a clinician is faced
with a critical haemorrhage in a previously healthy indi-
vidual. We describe the sequential occurrence of throm-
bosis and haemorrhage developing over a nine day
period in a young woman with a prolonged aPTT ratio.
Case presentation
Description
A 37 year old woman presented to casualty for pain and
swelling in the right calf; her Well’ss c o r ew a s5 ,D -
dimer elevated at 422 ng/ml (cut-off limit 230 ng/ml)
and a Doppler ultrasound revealed a clot in the upper
portion of the right femoral vein and in the deep veins
of the right calf. With regards to thrombosis risk factors,
she was 5 weeks post caesarean delivery, had been on
oral contraception for the previous three weeks, had a
body mass index of 24.5 (normal 18.5-24.9) had no vari-
cose veins, and had not been on any long haul trips by
either plane or car since delivery. Her personal history
was uneventful, this being her first pregnancy during
which she had no complications. There was no family
history of thrombosis or recurrent miscarriages. Her
aPTTr was 3.01 (normal range 0.88 -1.16) and pro-
thrombin time ratio (PTr) was normal. Her Hb was 9.1
g/dl with a slight microcytosis. Low molecular weight
heparin (LMWH) at treatment dose was started embri-
cated with warfarin then stopped after four days when
her international normalised ratio (INR) was 2.3. A
week later she re-attended casualty for spontaneous
bruising on upper limbs and worsening of the pain and
swelling in the right leg that was markedly ecchymotic.
Blood tests on admission revealed Hb 8.1 g/dl, platelets
557 × 10
9/L and C-reactive protein at 247 mg/L (normal
< 5 mg/L). Urine and blood cultures were negative.
Since 1988 in Airedale the possibility of a bleeding dis-
order was tested by comparing the clotting times of two
aPTT reagents, currently Synthesil (IL) as the reagent
sensitive to factor inhibitors and deficiencies and Actin
FS (Dade) as the reagent insensitive to factor inhibitors
and deficiencies but sensitive to factor XII deficiency
[2]. Unbeknown to the laboratory personnel the same
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[3]. Both assays are run on an automated coagulometer
(TOP-CTS, Instrumentation Laboratories). The patient’s
INR was 2.3 (due to warfarin), the Synthesil aPTTr was
disproportionately prolonged at 5.03 whereas the Actin
FS aPTTr was 3.21 and a thrombin time was 12.8” (nor-
mal 12-16.5”) ruling out a possible residual effect of
LMWH that had been stopped three days earlier. Given
the prolongation of both aPTTs, the laboratory person-
nel informed the consultant haematologist of a possible
factor inhibitor and pursued factor assays that revealed
a factor VIII at 2 IU/dl (normal range 60-180 IU/dl),
factor XII at 65 IU/dl (normal range 50-180 IU/dl), fac-
tor XI at 61 IU/dl (normal range 60-140 IU/dl) and fac-
tor IX at 46 IU/dl (normal range 50-150 IU/dl). A factor
VIII inhibitor was detected at 35 Bethesda Units. A
repeat Doppler US of the right lower limb did not show
thrombus in the femoral vein but extensive haematoma
in the calf obscuring the possibility of persistent throm-
bus. The following day her Hb had dropped to 6.9 g/dl:
warfarin was stopped and the patient was given a total
dose of 8 mg of recombinant VIIa intravenously,
repeated two hourly 12 times after transfer to the Hae-
mophilia Centre at Bradford Royal Infirmary. The
patient was started on oral cyclophosphamide 100 mg
daily continued for six months and prednisolone 1 mg/
kg for 6 weeks, gradually tapered down over the ensuing
five months: three weeks into immune suppression her
factor VIII levels was 36 IU/dl and in June 2010 her fac-
tor VIII was 62 IU/dl with normal aPTTs. A thrombo-
philia screen done at the same time (plasma levels of
protein C, protein S, antithrombin and gene testing for
factor V Leiden and prothrombin mutation, anticardioli-
pin antibodies and lupus anticoagulant) was negative. At
16 months follow up she is inhibitor negative with nor-
mal plasma factor VIII level.
Discussion
Our patient shifted from deep vein thrombosis (DVT) to
bleeding within the span of nine days: those involved in
her care had not noticed that her aPTTr had been getting
higher throughout her pregnancy (Table 1) and that it
was markedly abnormal at her attendance for DVT. A
factor VIII level at 2% and a factor VIII inhibitor at 35
Bethesda units were unequivocal with respect to preg-
nancy related acquired haemophilia: the latter is a life-
threatening antibody-mediated haemorrhagic disorder
that occurs prevalently in people over 50 years of age
presenting with bleeding and/or with a prolonged aPTT.
The FVIII inhibitor may develop during and/or after
pregnancy with a prevalence of 7% to 21% according to
series. It appeared in the first pregnancy in 80% (16 of
2 0 )o fw o m e na n dd i dn o ts e e mt or e c u rw i t hf u r t h e r
pregnancies [4-10] though in one survey it recurred in
the three women who had successive pregnancies [11]. In
general the inhibitor is identified on occasions of overt
bleeding: in one series 50% of bleeding occurred in the
peri-partum period and in 50% within 30 days of delivery;
in another series bleeding occurred pre-partum in two
women, within three days of delivery in three and within
3-12 months in nine [11,12]. Another review showed that
3% of 27 women bled during pregnancy, 3% after an
abortion, 15% immediately after delivery, 30% within 4
months and another 30% between 4 to 12 months of
delivery; this review also shows that post-partum factor
VIII inhibitor often disappears spontaneously [12].
However, prior to haemorrhage, our patient had suf-
fered a DVT, quite a rare occurrence in the presence of
a bleeding diathesis. In the absence of genetic or
acquired thrombophilia, four haemophilia A patients
developed spontaneous limb vein occlusions [13-16],
one with a duplicated superficial femoral vein [16]
whereas a haemophilia A youngster who was also factor
V Leiden heterozygous suffered a spontaneous cerebral
infarction [17].
Conversely two haemophilia A patients with inherited
thombophilia developed a fatal pulmonary embolism
and a DVT after a surgical challenge [18,19] whereas a
severe haemophilia A patient also factor V Leiden het-
erozygous suffered portal vein thrombosis after continu-
ous infusion of F VIII [20]. DVT has been described
also in a haemophilic A patient with factor VIII inhibi-
tor 18 days after recombinant activated factor VII infu-
sion [21].
Table 1 Evolution of coagulation tests since late pregnancy
2009 2010 Range
Sept 30 Dec 31 Jan 2 Mar 3 Mar 10 Mar 12
Gestational age (weeks) 26 39 39
Puerperium
(weeks)
56 6
PTr 1.00 0.90 1.03 1.26 2.05 2.32 0.9-1.12
aPTTr 1.01 1.23 1.32 3.01 9.31 5.03 0.88-1.16
FNG (mg/dl) 638 > 700 816 538 701 691 150-400
Prothrombin time ratio (PTr), activated partial thromboplastin time ratio (aPTTr) and fibrinogen (FNG) from the end of the second trimester of pregnancy
(September 30) to end of puerperium (Mar 12)
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described a spontaneous DVT in a 60 year old woman
and in an 80 year old man with splenic marginal zone
lymphoma and a proximal leg vein occlusion after a
femoral to popliteal by-pass in a 76 year old man [22];
pulmonary embolism developed in a 29 year old man
who was on tranexamic acid to minimise bleeding epi-
sodes that were managed with recombinant factor VII
when occurring acutely [23]: none of these patients had
inherited or acquired thrombophilia.
Within the thrombosis setting a prolonged aPTTr may
indicate the presence of a lupus anticoagulant (LA). In
the flurry of the Friday afternoon when the acquired fac-
tor VIII inhibitor was detected, whilst the patient was
administrated the first dose of recombinant factor VII
and then transferred to Bradford Royal Infirmary, we
overlooked that the Actin FS aPTTr was shorter than
the Synthesil aPTTr (3.21 vs 5.03): a study comparing
sensitive and insensitive reagents to the LA showed that
the shortening of the aPTTr with Actin FS (the insensi-
t i v er e a g e n t )c a nb es u g g e s t i v eo fL Ae v e ni np a t i e n t s
on oral anticoagulants and/or with acquired haemophilia
[3]. Hence we could not rule out that our patient also
had a LA that was not detected on subsequent testing
because of the immunosuppressive treatment she
received. Of the four reported cases where acquired fac-
tor VIII inhibitor coexisted with LA the clinical pheno-
type was always bleeding [24-27]. With regards to
haemophiliacs with anti-factor VIII inhibitors, one study
showed a simultaneous LA detected by the dilute Rus-
sell viper venom time (DRVVT) (and Staclot LA) in 12
such patients [28] whereas a positive LA was more com-
mon in haemophiliacs with anti-factor VIIII inhibitors
than in haemophiliacs without inhibitors either by
DRVVT (IL-LAC screen and confirm) (22% vs 10%) or
by Staclot LA (Stago, France) (30% vs 5%).
Conclusion
Thrombosis and bleeding are the yin-yang of haemosta-
sis and their simultaneous occurrence must alert us to
the rarity and complexity of such occurrences and
induce us to have a sharp insight in these cases:
acquired haemophilia A developing post-partum is not
uncommon, a vascular occlusion on the background of
acquired haemophilia A followed by bleeding aggravated
by warfarin is unusual indeed. Given the differences in
the Synthesil and Actin FS aPTT ratios, we cannot rule
out that DVT was also promoted by a LA that might
have disappeared after immune suppressive treatment:
strict adherence to existing guidelines for LA testing
[29] should have lead us to perform also a DRVVT
(screen and confirm) to shed further light on the throm-
botic event.
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